Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study
NCT05492695 · Diamond Headache Clinic · PHASE4 · terminated · last registry update 2023-09-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Stopped from financial sponsor due to inability to enroll participants.” | – | Registry record, Diamond Headache Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-09Results posted on the registry: H. Lundbeck A/S, Eptinezumab + Placebo (NCT04688775)
- 2024-08-06Results posted on the registry: H. Lundbeck A/S, Eptinezumab (NCT05064397)
- 2024-06-18Results posted on the registry: Eli Lilly and Company, Galcanezumab + Rimegepant (NCT05127486)
- 2024-05-29Results posted on the registry: H. Lundbeck A/S, Eptinezumab + Erenumab (NCT05284019)
- 2024-05-29Also stopped (terminated): H. Lundbeck A/S, Eptinezumab + Erenumab (NCT05284019)
- 2024-05-24Phase 3 first posted: Dr George Medvedev, Eptinezumab (NCT06428838)
- 2023-10-02Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT04041284)
- 2023-06-09Phase 3 first posted: H. Lundbeck A/S, Eptinezumab + Placebo (NCT05897320)
- 2023-03-30Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT03965091)
- 2023-03-30Also stopped (terminated): Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT03965091)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision